simplyStocks
BioMarin Pharmaceutical Inc.
BMRN · NASDAQHealthcare
The economic chain
Follow the chain left → right, from inputs to end demand. Tap any company to trace its links.
Raw inputs
Equipment
Foundry
Chip design
Software
AI demand
—
Company details
Market cap
$11B
P/E ratio
33×
Div yield
0%
EPS (TTM)
$1.80
Profit margin
11%
Rev. growth
+13%
Revenue
$3.2B
Non-GAAP EPS
$3.15
In plain English
BioMarin is a rare-disease specialist — it grows biologic enzymes in bioreactors and sells a handful of high-priced therapies for genetic disorders so uncommon that few rivals bother. Its growth engine is Voxzogo for children with achondroplasia (dwarfism); the rest is a durable base of enzyme-replacement drugs for lysosomal and metabolic diseases. On $3.2B of 2025 revenue it now turns a GAAP profit, with roughly three-quarters of Voxzogo sales coming from outside the US.
In simple terms
What BioMarin Pharmaceutical Inc. really sells
BioMarin is a rare-disease specialist — it grows biologic enzymes in bioreactors and sells a handful of high-priced therapies for genetic disorders so uncommon that few rivals bother. Its growth engine is Voxzogo for children with achondroplasia (dwarfism); the rest is a durable base of enzyme-replacement drugs for lysosomal and metabolic diseases. On $3.2B of 2025 revenue it now turns a GAAP profit, with roughly three-quarters of Voxzogo sales coming from outside the US.
Tip · Click any company in the map to learn — in one sentence — what it actually does and why it matters.
Risk read
SteadierMore speculative
Why this rating?